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Essential Medium; MGP, muscle glycogen phosphorylase; PP1C, catalytic sub-unit of 
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genePPP1R6(3D).
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ABSTRACT 
 
Hepatic insulin resistance in the leptin-receptor defective Zucker fa/fa rat is associated 
with impaired glycogen synthesis and increased activity of phosphorylase-a. We 
investigated the coupling between phosphorylase-a and glycogen synthesis in 
hepatocytes from fa/fa rats by modulating the concentration of phosphorylase-a. 
Treatment of hepatocytes from fa/fa rats and Fa/? controls with a selective 
phosphorylase inhibitor caused depletion of phosphorylase-a, activation of glycogen 
synthase and stimulation of glycogen synthesis. The flux-control coefficient of 
phosphorylase on glycogen synthesis was glucose dependent and at 10 mM glucose 
was higher in fa/fa than Fa/? hepatocytes. There was an inverse correlation between 
the activities of glycogen synthase and phosphorylase-a in both fa/fa and Fa/? 
hepatocytes. However, fa/fa hepatocytes had a higher activity of phosphorylase-a, for 
a corresponding activity of glycogen synthase. This defect was, in part, normalized by 
expression of the glycogen-targeting protein, PTG. Hepatocytes from fa/fa rats had 
normal expression of the glycogen-targeting proteins GL and PTG but markedly 
reduced expression of R6. Expression of R6 protein was increased in hepatocytes 
from Wistar rats after incubation with leptin and insulin. Diminished hepatic R6 
expression in the leptin-receptor defective fa/fa rat may be a contributing factor to the 
elevated phosphorylase activity and/or its high control strength on glycogen synthesis. 
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INTRODUCTION 
 
Type 2 diabetes is associated with impaired glucose-induced insulin secretion 
and insulin resistance in the liver and periphery. Hepatic insulin resistance is 
attributed to a range of metabolic defects, which include impaired glucose tolerance in 
the absorptive state and lack of inhibition of hepatic glucose production by 
hyperglycaemia and hyperinsulinaemia [1,2]. 
The Zucker fa/fa rat and diabetic db/db mouse, which develop 
hyperinsulinaemia as a result of mutations in the leptin receptor gene have been 
widely used as animal models for insulin resistance and type 2 diabetes because they 
show both hepatic and peripheral insulin resistance [3–7]. The hepatic defect in the 
fa/fa rat and db/db mouse involves various enzyme abnormalities including elevated 
activities of glycolytic and lipogenic enzymes [8], phosphorylase [9–12] and glycogen 
synthase phosphatase [13–15]. It has been proposed that the increased activity of 
phosphorylase is a contributing factor to impaired hepatic glycogenesis in the fa/fa rat 
[11]. This hypothesis was supported by the high flux-control coefficient of 
phosphorylase-a on glycogen synthesis in hepatocytes from Wistar rats under 
metabolic conditions associated with negligible cycling between glycogen synthesis 
and degradation [16], and by the finding that in hepatocytes, unlike in muscle, 
inactivation of phosphorylase rather than inactivation of glycogen synthase kinase-3 is 
a major component of the mechanism by which insulin stimulates glycogen synthesis 
[17]. 
In liver cells there is reciprocal control between the activity of phosphorylase-
a and the activation state of glycogen synthase, through allosteric inhibition of 
glycogen synthase phosphatase by binding of phosphorylase-a (the phosphorylated 
form of the enzyme) to the C-terminus of the glycogen-targeting protein GL[18,19]. 
However, this mechanism alone cannot account for the high control strength of 
phosphorylase on glycogen synthesis in hepatocytes from Wistar rats [16,17] or for 
the impaired glycogen synthesis in hepatocytes from Zucker fa/fa rats, which do not 
have diminished glycogen synthase activity [7,11,20]. GL is one of four glycogen-
targeting proteins expressed in liver [21–25]. These proteins have binding sites for 
protein phosphatase-1 (PP1) and for glycogen, and they differ in their relative 
activities of glycogen synthase phosphatase and phosphorylase phosphatase. They are 
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designated GL or R4, PTG or R5, R6 and R3E [21–25]. The glycogenic effects of GL 
and PTG/R5 in hepatocytes have been demonstrated by adenovirus-mediated enzyme 
overexpression in hepatocytes [26–28]. However, the contribution of these targeting 
proteins to the increased activity of glycogen synthase phosphatase in hepatocytes 
from Zucker fa/fa rats [13–15] has not been explored. 
Potent and selective inhibitors of phosphorylase are now available [29,30] 
which are very powerful experimental tools for selectively modulating either the 
activity of phosphorylase or the concentration of phosphorylase-a in hepatocytes [31]. 
They enable investigation into the relative roles of phosphorylase-a, an allosteric 
ligand of GL, as distinct from phosphorylase activity, a determinant of glycogen 
degradation. In this study we used independent approaches to modulate the activity of 
phosphorylase or concentration of phosphorylase-a in hepatocytes to determine the 
mechanism by which phosphorylase contributes to the hepatic defect in the Zucker 
fa/fa rat. 
 
RESEARCH DESIGN AND METHODS 
 
Materials- CP-91149 [30] was a generous gift from Pfizer Global Research and 
Development (Groton/New London Laboratories, USA). 
 
Hepatocyte isolation and culture:   Male, Zucker, 11–13-week-old, genetically 
obese (fa/fa) or lean (Fa/?) rats (body weight: fa/fa 461 ± 10 g; Fa/? 311 ± 5 g, n = 16, 
P < 0.001) were used throughout this study, except for the experiments in Fig. 6 
where female (9–11-week-old) Zucker rats were used (body weight: fa/fa 323 ± 12 g; 
Fa/? 200 ± 5 g, n = 4, P < 0.001). They were obtained either from AstraZeneca 
(Alderley Park, UK) or from Harlan Olac (Bicester, UK). All experiments were 
carried out in accordance with EC Council Directive (86/609/EEC). Hepatocytes were 
isolated by collagenase perfusion of the liver and suspended in minimal essential 
medium (MEM) supplemented with 5% (v/v) newborn calf serum and cultured in 
monolayer [11]. After cell attachment (2–4 h), they were cultured in serum-free MEM 
containing 10 nM dexamethasone for 18 h. 
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Treatment with adenoviruses:   After cell attachment (2 h), the medium was 
replaced by serum-free MEM containing varying titres of recombinant adenovirus for 
expression of muscle glycogen phosphorylase [41], glucokinase [42] or PTG [43]. 
After 2 h, the medium was replaced with serum-free MEM containing 10 nM 
dexamethasone and the cells were cultured as above. 
 
Metabolic studiesAll metabolic studies were performed after culture of the 
hepatocytes for 18 h. To determine glycogen synthesis, hepatocyte monolayers were 
incubated for 3 h in MEM containing [U-14C]glucose and 10 mM glucose unless 
otherwise indicated, without or with inhibitors as indicated. To determine 
glucokinase, glycogen synthase and phosphorylase, parallel incubations were 
performed without radiolabel. Glycogen synthesis was determined by ethanol 
precipitation of the glycogen as described previously [11] and is expressed an nmol of 
glucose incorporated per 3 h per mg protein. 
 
Enzyme activity determination:   Glucokinase activity (free and bound) was 
determined spectrometrically after permeabilization of the hepatocytes with digitonin 
[32]. To determine phosphorylase and glycogen synthase, cells were snap-frozen in 
liquid nitrogen [16]. Phosphorylase-a was assayed spectrometrically by coupling to 
phosphoglucomutase and glucose 6-phosphate dehydrogenase [38]. Total 
phosphorylase (a + b) was determined radiochemically [44] in the homogenate and 
13 000 g supernatant after incubation of the extracts with phosphorylase kinase [11]. 
The activity of the phosphorylase in cells treated with adenovirus for expression of 
MGP (Fig. 2A) was determined in the presence 5 mM AMP [16], representing liver 
phosphorylase-a and muscle a + b. Active or total glycogen synthase were determined 
without or with glucose 6-phosphate, respectively [45]. The activities of 
phosphorylase and of active glycogen synthase are expressed as munits/mg protein. 
 
Metabolic Control Analysis:   Flux-control coefficients of phosphorylase-a on the 
rate of glycogen synthesis were determined from the initial slope of double log plots 
of the rate of glycogen synthesis against the activity of phosphorylase-a, as described 
previously [16,36,37]. 
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Immunoreactive protein:    Protein expression of the glycogen-targeting proteins: 
GL, PTG and R6 was determined on the hepatocyte suspensions and monolayer 
cultures using affinity-purified antibodies provided by P.T. Cohen raised in sheep to 
the GST-GL, protein (GL); peptide GYPNGFQRRNFVNK (R5/PTG) and 
RPIIQRRSRSLPTSPE (R6). The characterization of these antibodies has been 
reported previously [22]. Total phosphorylase expression was determined on the 
monolayer cultures using a commercial mouse antibody (BB Clone 3G1, from 
Research Diagnostics). Protein of cell lysates (20–30 µg) were resolved by 
SDS/PAGE and after electrotransfer of protein to nitrocellulose, membranes were 
probed with the primary antibody (0.1–0.2 µg·mL−1 affinity purified antibodies or 
1 : 1000 for phosphorylase) followed by the appropriate peroxidase conjugated anti-
IgG (Jackson Immuno-Research, West Grove, PA) and visualization with an ECL kit 
(Amersham Pharmacia Biotech, Piscataway, NJ). 
 
Statistical Analysis:  Results are expressed as means ± SE. Statistical analysis was 
carried out using the Student's t-test (either paired or unpaired). 
 
RESULTS 
 
High activities of glucokinase and phosphorylase in hepatocytes from fa/fa rats 
Hepatocytes from fa/fa rats had a higher total activity of glucokinase (Fa/? 
5 ± 1 munits·mg−1; fa/fa 8 ± 1 munits·mg−1P < 0.01) and a higher proportion of this 
activity was present in the free (unbound) state (Fa/? 41 ± 3%; fa/fa 51 ± 2%, P < 0.05 
n = 6). The relation between glycogen synthesis and glucokinase activity was 
determined by overexpression of glucokinase with varying titres of recombinant 
adenovirus. Although glycogen synthesis increased with titrated glucokinase 
expression, as expected [32], it was lower in fa/fa hepatocytes for a corresponding 
glucokinase activity (Fig. 1A). The total activity of phosphorylase (a + b) assayed in 
the whole homogenate and in the 13 000 g supernatant was 24 and 48% higher, 
respectively, in hepatocytes from fa/fa rats compared with Fa/? controls (Fig. 1B). 
Immunoreactivity to total phosphorylase determined in the whole homogenate was 
slightly, but not significantly, higher in fa/fa hepatocytes (Fig. 1C). The total activity 
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of glycogen synthase was the same in hepatocytes from Fa/? and fa/fa rats (1.5 ± 0.3 
versus 1.5 ± 0.3 munits·mg−1). 
 
Effects of expression of muscle glycogen phosphorylase 
To test whether a higher activity of phosphorylase can account for the lower rate of 
glycogen synthesis in fa/fa hepatocytes we expressed the muscle isoform of glycogen 
phosphorylase (MGP), which, unlike the liver isoform, is catalytically active in the 
dephosphorylated state (phosphorylase b) at physiological AMP concentrations [16]. 
Titrated MGP expression in hepatocytes causes inactivation of glycogen synthase and 
inhibition of glycogen synthesis [16]. In this study, expression of MGP was 
determined from phosphorylase activity assayed in the presence of AMP, which was 
increased between 1.5- and 5-fold (Fig. 2A). Phosphorylase-a activity, assayed in the 
absence of AMP, was increased by a lesser extent (1.2 to 1.7-fold, Fig. 2B) because 
the expressed MGP is only partly phosphorylated [16]. MGP expression was 
associated with inactivation of glycogen synthase and inhibition of glycogen 
synthesis. The rate of glycogen synthesis, but not the activity of glycogen synthase, 
inversely correlated with the activity of phosphorylase-a in hepatocytes 
overexpressing MGP (Fig. 2C,D), suggesting that the increased activity or 
concentration of phosphorylase-a is a contributing factor to the glycogenic defect 
(Fig. 2D) and that there is altered coupling between phosphorylase-a and glycogen 
synthase in fa/fa compared with Fa/? hepatocytes (Fig. 2C). 
 
Effects of activity and concentration of phosphorylase-a on glycogen synthesis 
To test the role of the phosphorylated form of phosphorylase independently of 
changes in total phosphorylase concentration, we used CP-91149, an indole 
carboxamide phosphorylase inhibitor [30], which causes conversion of 
phosphorylase-a to -b with concomitant activation of glycogen synthase and 
stimulation of glycogen synthesis [16,31]. CP-91149 caused depletion of 
phosphorylase-a but did not abolish the difference in phosphorylase-a between 
hepatocytes from fa/fa and Fa/? rats (P < 0.03 at 10 µM CP-91149). When the 
activation of glycogen synthase and stimulation of glycogen synthesis were plotted 
against the corresponding activity of phosphorylase-a there was a rightward shift in 
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both glycogen synthase against phosphorylase-a (Fig. 3B) and glycogen synthesis 
against phosphorylase-a (Fig. 3C) curves for fa/fa compared with Fa/? hepatocytes. 
To test the role of phosphorylase activity, as distinct from the phosphorylation state of 
the enzyme, we used 1,4-dideoxy-1,4-imino-D-arabinitol (DAB), a potent inhibitor of 
phosphorylase and of glycogenolysis in hepatocytes with an IC50 < 2 µM[33,34], 
which unlike CP-91149, does not cause conversion of phophorylase-a to -b [31]. 
Treatment of hepatocytes from fa/fa rats with DAB (5–20 µM) did not stimulate 
glycogen synthesis (control, 9.5 ± 1.3; 5 µM DAB, 8.7 ± 1.6; 10 µM DAB, 8.6 ± 1.6; 
20 µM DAB, 5.2 ± 1.2 nmol·3 hmg−1, n = 10). Inhibition at 20 µM DAB (P < 0.002) 
was associated with inactivation of glycogen synthase (0.42 ± 0.06 to 
0.27 ± 0.07 munits·mg−1, P < 0.002) and is explained by conversion of phosphorylase-
b to phosphorylase-a [31]. The lack of stimulation of glycogen synthesis by lower 
DAB concentrations (5–10 µM), which inhibit glycogenolysis [34], is consistent with 
a lack of cycling between synthesis and degradation [35] confirming that stimulation 
of glycogen synthesis by CP-91149 is not due to inhibition of glycogen degradation 
and also the impaired glycogen synthesis in fa/fa hepatocytes is not due to increased 
glycogen degradation. 
 
Effects of overexpression of the glycogen targeting protein PTG 
The rightward shift in the inverse correlation between glycogen synthase against 
phosphorylase-a in fa/fa and Fa/? hepatocytes (Figs 2C,3B) could be explained by an 
increased activity of glycogen synthase phosphatase [13–15], because of increased 
expression of glycogen-targeting proteins [26,27], or by decreased coupling between 
the glycogen-targeting protein GL and its allosteric inhibitor phosphorylase-a, because 
of altered subcellular distribution of phosphorylase-a or impaired access to GL. We 
determined the effects of expression of the targeting protein, PTG, which causes both 
dephosphorylation of phosphorylase-a and activation of glycogen synthase [28]. 
Overexpression of PTG caused inactivation of phosphorylase (Fig. 4A), activation of 
glycogen synthase and stimulation of glycogen synthesis. Unlike CP-91149, it 
partially counteracted the rightward shift of the glycogen synthase against 
phosphorylase-a curve (Fig. 4B). However, it did not abolish the rightward shift of the 
glycogen synthesis against phosphorylase-a (Fig. 4C). Because PTG mimics the 
effects of CP-91149 on phosphorylase inactivation, but has a greater effect on 
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translocation of glycogen synthase and phosphorylase [28], these results suggest that a 
defect in glycogen-targeting proteins may account for the shift in the glycogen 
synthase against phosphorylase curves. 
 
Higher sensitivity of glycogen synthesis to phosphorylase-a in fa/fa hepatocytes 
To test whether impaired glycogen synthesis in hepatocytes from fa/fa rats can be 
explained by an altered sensitivity of flux to phosphorylase-a concentration, we used 
metabolic control analysis [36,37] to determine the flux-control coefficient of 
phosphorylase-a on glycogen synthesis from the initial slope of the double log plot of 
glycogen synthesis against phosphorylase-a for the three experimental conditions 
(incubation with CP-91149 or expression of MGP and PTG) that alter phosphorylase 
activity (Figs 2–4). The linear plot for the data is shown in Fig. 5A and the 
corresponding plot for active glycogen synthase against phosphorylase-a is shown in 
Fig. 5B. PTG expression was more effective than CP-91149 in attenuating the 
rightward shift for glycogen synthase against phosphorylase-a (Fig. 5B). Flux-control 
coefficients, which represent the fractional change in flux resulting from a fractional 
change in phosphorylase-a, were approximately twofold higher in fa/fa hepatocytes 
(Fig. 5C). 
 
Relation between the flux control coefficient and glucose concentration   
In the above experiments the flux-control coefficients of phosphorylase-a on glycogen 
synthesis were determined from incubations with 10 mM glucose. Because the 
glycogenic defect in hepatocytes from fa/fa rats is observed at 10 mM, but not 25 mM, 
glucose [11], we also determined flux-control coefficients for phosphorylase-a on 
glycogen synthesis at varying glucose concentrations. Flux-control coefficients were 
highest at 5 mM glucose, and were significantly higher in fa/fa hepatocytes at 5–
15 mM glucose with a crossover at 20 mM glucose (Fig. 6). These experiments were 
performed on hepatocytes from 7–9-week-old female Zucker rats, which have higher 
rates of glycogen synthesis and lower activities of phosphorylase-a and flux-control 
coefficients than hepatocytes from 11–13-week-old male rats. 
 
Expression of glycogen targeting proteins in hepatocytes from fa/fa rats 
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To test whether the defect in hepatocytes from fa/fa rats is associated with altered 
expression of GL, PTG- or R6-targeting proteins, we determined immunoreactivity by 
western blotting using isoform-specific antibodies [22]. Hepatocytes from fa/fa rats 
had similar expression of GL and PTG as Fa/? controls but markedly decreased 
expression of R6 (Fig. 7). 
 
Effects of leptin and insulin on hepatocytes from Wistar rats 
Because fa/fa rats are homozygous for a mutation in the leptin receptor gene, we 
tested whether expression of R6 is regulated by leptin in hepatocytes from Wistar rats. 
The activity of phosphorylase-a was decreased by culture of hepatocytes with leptin 
and insulin (Fig. 8A) in agreement with previous findings [38]. R6 protein was 
increased by 75% after combined culture with leptin and insulin (Fig. 8B). 
 
DISCUSSION 
 
 The Zucker fa/fa rat is widely used as a model for insulin resistance and type 2 
diabetes because it shows impaired glucose tolerance and lack of suppression of 
hepatic glucose production in response to hyperglycaemia [3–7]. The hepatic enzyme 
abnormalities include impaired hepatic glycogen synthesis and increased activities of 
phosphorylase-a [11,12] and glycogen synthase phosphatase [13–15]. However, the 
total activity of glycogen synthase and the activation state are the same as in control 
hepatocytes [6,11]. 
 In this study, we used three approaches to modulate the concentration and 
activity of phosphorylase-a, to determine its role in the glycogenic defect. We applied 
metabolic control analysis to test whether the glycogenic defect in hepatocytes from 
fa/fa rats is due to higher phosphorylase activity or to changes in coupling 
mechanisms between phosphorylase-a and glycogen synthesis. Using three 
independent methods involving either expression of the muscle isoform of glycogen 
phosphorylase, or expression of the glycogen-targeting protein PTG or incubation 
with a selective phosphorylase inhibitor [30] that promotes dephosphorylation of 
phosphorylase-a [31], we determined the flux-control coefficient of phosphorylase on 
glycogen synthesis. This is a measure of the sensitivity of flux to small incremental 
changes in phosphorylase-a concentration or activity [36,37]. It is a property of the 
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entire metabolic system and depends on the concentrations of other proteins that 
influence the flux through that pathway. 
This study shows that the flux-control coefficient of phosphorylase on 
glycogen synthesis determined at 10 mM glucose is higher in hepatocytes from fa/fa 
than Fa/? rats and also that there is a rightward shift in the plots of glycogen synthesis 
against phosphorylase-a or glycogen synthase against phosphorylase-a in fa/fa 
compared with Fa/? hepatocytes, which is indicative of a difference in coupling 
between glycogen synthase and phosphorylase-a. 
Flux-control coefficients can be positive or negative, and values greater than 
unity are rare [37] and indicative of protein–protein interaction and/or downstream 
mechanisms that act synergistically. Glucokinase has a flux-control coefficient on 
glycogen synthesis that is greater than unity at low glucose [32], and this is explained 
by glucokinase binding to an inhibitory regulator protein [39]. Phosphorylase-a, like 
glucokinase also has a very high flux-control coefficient of glycogen synthesis, 
particularly at low glucose concentrations. However, unlike in the case of 
glucokinase, the mechanisms that account for this high control are not fully 
understood [16]. We can rule out a role for cycling between glycogen synthesis and 
degradation as a contributory factor to the high control coefficient of phosphorylase 
on glycogen synthesis because using a potent inhibitor of phosphorylase (DAB) that 
does not promote conversion of phosphorylase-a to -b [31], it can be shown that there 
is negligible cycling between glycogen degradation and synthesis [31,35]. Although 
allosteric inhibition of glycogen synthase phosphatase in association with GL is a 
component of the high control strength of phosphorylase-a [16], several lines of 
evidence show that this mechanism alone cannot explain the high control strength on 
glycogen synthesis. One compelling argument is the evidence that inhibitors of 
glycogen synthase kinase-3 cause marked activation of glycogen synthase but 
negligible stimulation of glycogen synthesis [17]. This contrasts with the more 
moderate activation of glycogen synthase by CP-91149 but its greater potency at 
stimulating glycogen synthesis [17]. Likewise, the potency of PTG overexpression at 
stimulating glycogen synthesis in hepatocytes when compared with 
dephosphorylation of phosphorylase-a caused by CP-91149 suggests that 
translocation of glycogen synthase and phosphorylase is a key contributory factor to 
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the glycogenic stimulation [28]. We therefore determined the expression of three 
glycogen-targeting proteins that are known to be expressed in liver. 
GL is thought to be the predominant glycogen-targeting protein in liver [25]. It 
is the only glycogen-targeting protein that is known to have an allosteric site for 
phosphorylase-a, which causes inhibition of synthase phosphatase activity [21], 
accordingly, phosphorylase-a prevents activation of glycogen synthase only in cells 
expressing GL. In agreement with this model, CP-91149 does not cause activation of 
glycogen synthase in hepatoma cell lines that lack GL expression (L. Hampson & L. 
Agius, unpublished results). GL enhances the activity of PP1 on glycogen synthase but 
suppresses dephosphorylation of phosphorylase-a [21]. It is therefore presumed to 
function as a synthase phosphatase [21]. Nonetheless, overexpression of GL in 
hepatocytes inactivates phosphorylase, indicating that it does function as a 
phosphorylase phosphatase [27]. PTG and R6, unlike GL, are expressed ubiquitously 
[22–24]. Expression of PTG in hepatocytes is associated with inactivation of 
phosphorylase and activation of glycogen synthase and translocation of these proteins 
[26–28]. The expression of GL and PTG, but not R6, in rat liver in vivo is insulin-
dependent. It declines during insulin deficiency and is restored by insulin treatment 
[22,40]. Another glycogen-targeting protein expressed in rat liver and designated 
PPP1RE may also be insulin dependent based on changes in mRNA levels [25]. It is 
noteworthy that assays of PP1 activity in immunoprecipitates of the glycogen-
targeting proteins GL, PTG, R6 and PPP1RE have shown in all cases 
dephosphorylating activity with both glycogen synthase and phosphorylase as 
substrates. However, whether these activities function as synthase phosphatase (as 
suggested for GL) or as phosphorylase phosphatase (as suggested for PTG) in vivo 
remains speculative [22,25]. We found no evidence for changes in expression of 
either GL or PTG in hepatocytes from fa/fa rats. However, we demonstrate that 
expression of R6 protein is markedly decreased in hepatocytes from fa/fa rats. To our 
knowledge this is the first report of adaptive changes in hepatic R6 protein. The main 
distinguishing feature of hepatic R6 compared with GL, PTG and PPP1RE, in addition 
to its lack of adaptive change with altered insulin status, is that the protein is 
recovered mainly from the soluble and microsomal fractions rather than the glycogen 
fraction of liver extracts [22,40], presumably because of a lower glycogen-binding 
affinity. This implicates a distinct function from the other targeting proteins. 
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 Based on assays of phosphorylase phosphatase and glycogen synthase 
phosphatase in both the glycogen fraction and the soluble fraction, R6 appears to have 
a negligible contribution to phosphatase activity in the glycogen fraction but it can 
account for as much as 20% of total phosphorylase phosphatase activity in the cell 
lysate fraction [22]. A key question is whether the markedly reduced expression of R6 
in hepatocytes from fa/fa rats could contribute to the elevated phosphorylase-a and the 
glycogenic defect? Both the activity of phosphorylase-a in hepatocytes and the control 
strength of phosphorylase on glycogen synthesis are markedly dependent on the age 
of the rat (S. Aiston & L. Agius, unpublished results). Hepatocytes from 6-week-old 
rats have a high rate of glycogen synthesis, a low activity of phosphorylase-a and a 
low flux-control coefficient on glycogen synthesis. With age, glycogen synthesis 
declines and both the activity of phosphorylase-a and its control coefficient on 
glycogen synthesis increase markedly. Downregulation of phosphorylase-a activity by 
leptin is observed in 10-week-old rats but not in 6-week-old rats. A tentative 
hypothesis to explain a putative link between impaired R6 expression in hepatocytes 
from fa/fa rats and the elevated activity of phosphorylase-a is that R6 may be involved 
in the mechanism by which leptin downregulates phosphorylase activity. Our finding 
that culture of hepatocytes from Wistar rats with leptin and insulin is associated with 
increased expression of R6 protein with concomitant downregulation of 
phosphorylase-a activity is consistent with the hypothesis for a putative role for R6 in 
regulating phosphorylase-a activity and or subcellular location. This hypothesis would 
be strengthened by use of specific inhibitors of R6, but none are currently available, 
or by selective downregulation of R6 expression. 
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LEGENDS TO FIGURES 
 
Fig. 1.  Impaired glycogen synthesis and elevated phosphorylase activity in fa/fa 
hepatocytes.   A.  Glycogen synthesis determined during incubation with 10 mmol/l 
glucose in hepatocytes from fa/fa (filled symbols) and Fa/? (open symbols) rats with 
varying degrees of glucokinase overexpression by treatment with 4 titres of 
recombinant adenovirus. B.  Total phosphorylase activity (a + b) determined in the 
13,000g supernatant (SN) or in the whole homogenate (HOM) of hepatocytes from 
fa/fa  and Fa/? rats.   C.  Phosphorylase immunoreactivity (arbitary densitometry 
units) and represent immunoblot of 3 fa/fa () and 3 Fa/? ( ) preparations.  Data are 
means ± SE for n=6, (A), 15 (B) and 6, (C), * P < 0.05 relative to Fa/?. 
 
Fig.  2.  Expression of muscle glycogen phosphorylase inhibits glycogen synthesis 
Hepatocytes from fa/fa (filled symbols) and Fa/? (open symbols) rats were treated 
with the indicated titres (5-40 µl/ml) of adenovirus for expression of MGP.  
Hepatocytes were incubated for determination of glycogen synthesis and the activities 
of phosphorylase and glycogen synthase as described in Experimental procedures.  A.  
Phosphorylase activity assayed in the presence of AMP.  B.  Phosphorylase a activity 
C. Active glycogen synthase activity versus phosphorylase-a.  D.  Glycogen synthesis 
vs phosphorylase-a.  Data are the mean ± SE for n = 10.  * P < 0.05 relative to Fa/?. 
    
Fig. 3.  Effects of CP-91149 on glycogen synthesis and enzyme activities 
Hepatocytes from fa/fa (filled symbols) and Fa/? (open symbols) rats were incubated 
for 3 h with the concentrations of CP-91149 indicated for determination of glycogen 
synthesis and the activities of phosphorylase-a and glycogen synthase.  A.  
phosphorylase-a.  B.  active glycogen synthase versus phosphorylase-a.  C glycogen 
synthesis versus phosphorylase-a.  Data are mean ± SE for n = 15. 
 
Fig. 4.  Effects of PTG expression on glycogen synthesis and enzyme activities 
Hepatocytes from fa/fa (filled symbols) and Fa/? (open symbols) rats were treated 
with varying titres of adenovirus for expression of PTG and cultured for 18 h.   A.  
Hepatocytes were incubated for determination of glycogen synthesis and the activities 
of phosphorylase and glycogen synthase as in Fig. 2.  B.  Active glycogen synthase 
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versus phosphorylase-a.  C.  Glycogen synthesis versus phosphorylase-a.  Data are 
mean ± SE for n = 8. 
 
Fig. 5.  Sensitivity of glycogen synthesis to phosphorylase-a during enzyme 
expression or inactivation.    Linear plots of glycogen synthesis against 
phosphorylase-a (A) and active glycogen synthase against phosphorylase-a (B) for the 
data in Figs 2-4.  C. Flux-control coefficients determined from initial slope of the 
double log plot of glycogen synthesis against phosphorylase-a.   
 
Fig. 6.  Sensitivity of glycogen synthesis to phosphorylase-a as a function of glucose 
concentration.   Glycogen synthesis (A) was determined in hepatocytes from female 
Zucker fa/fa (filled symbols) and Fa/? (open symbols) rats during incubation with the 
glucose concentrations indicated without (round symbols) or with (square symbols)  
2.5 µmol/l CP-91149; B, phosphorylase-a activity.  C. Slope of double log plot of 
glycogen synthesis against phosphorylase-a.  Data are mean ± SE, n = 4, * P < 0.05. 
 
Fig. 7.  Expression of glycogen targeting proteins in fa/fa and Fa/? hepatocytes. 
Immunoreactivity to GL, PTG/R5 and R6 was determined in the freshly isolated 
hepatocyte suspensions as described in Experimental procedures and densitometry is 
expressed as relative arbitary units (AU).  Mean  ± SE for n = 7; representative blots 
for three fa/fa and three Fa/? preparations are shown together with the PTG marker.  * 
P < 0.0001 fa/fa vs Fa/? 
 
Fig. 8.   Effects of leptin and insulin on R6-mRNA levels and phosphorylase activity 
in hepatocytes from Wistar rats..   Hepatocytes were cultured for 18 h without or with 
10nmol/l insulin (I) and 500ng/ml leptin (L).  Parallel incubations were performed for 
determination of phosphorylase-a (A) and immunoreactive R6 (B).  Data are mean ± 
SE for n=8, * P < 0.05; **P < 0.005 relative to no additions. 
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